In this April 25, 2022 article for The Hill, Peter Sullivan reports that the US Food and Drug Administration (FDA) has granted full approval for remdesivir as a COVID-19 treatment for children under 12 years.

The approval covers children who are 28 days and older and who weigh at least 3 kilograms and are either hospitalized or at high risk of severe illness

Editor’s Note: What data did the FDA use to approve the use of remdesivir on kids?

Based on the evidence, remdesivir has been pretty damaging among adults [see New study: WHO data shows Remdesevir causes serious bradycardia among COVID-19 patients, WHO advises against use of remdesevir for COVID patients, Dr. Bryan Ardis: Remdesivir is the Real Cause of COVID Deaths].

How did the FDA determine that remdesivir would do better among children? [Also read WHO study shows remdesivir offers no benefit to COVID-19 patients].

To understand the dangers of remdesivir’s approval for children, we encourage you to watch this morning’s newscast by the Children’s Health Defense. [You might also want to read this letter to Dr. Malone: An Open Letter to Doctor Robert Malone (Inventor of mRNA biotechnology)].

Read Original Article